AB0804 Bone Manifestations in Patients with Gaucher Disease

Abstract

Background Gaucher Disease (GD), the most prevalent glycolipid storage disease, is an autosomal recessive metabolic disorder that is caused by an inherited deficiency of the lysosomal enzyme, glycocerebrosidase. This defect leads to reduce enzyme activity, resulting in the accumulation of glucosylceramide in cells of the monocyte-macrophages linage, known as Gaucher cells. Common presenting features include anemia, thrombocytopenia, hepatosplenomegaly and bone abnormalities. Skeletal disorders include osteopenia, bone pain crisis, bone infarctions, avascular bone necrosis (of the proximal and distal end of femur, proximal end of tibia and humerus), osteolytic lesions and fractures. Currently enzyme replacement therapy (ERT) has demonstrated a fast recovery of the cytopenias and visceromegalies. Besides, it has shown beneficial effects in both bone pain and the development of osteoporosis. Objectives The objective of this work was to analyze the clinical characteristics and bone involvement of Gaucher disease patients diagnosed and controlled in our department. Methods Descriptive study including Gaucher disease patients diagnosed in our department. In all patients we analyzed clinical and laboratory data (including PTH, 25OHD, P1NP and BCTX); bone mineral density of lumbar spine and femur and MRI of spine, femur, tibia and humerus bilaterally. Results 9 GD patients (6 men and 3 women) were studied, with a mean age of 48 years (34-70), with an average time of evolution of the illness of 21 years (2-43). Currently, all patients receive ERT, with a mean duration of 10,5 years (1-16). Most of them (n=6) started with bone symptoms such as pain and bone crisis. Before received ERT, patients developed the following bone abnormalities: bone infarctions in 8 patients (89%), Erlenmeyer flask deformity in 2 patients, femur avascular necrosis in 5 patients, 80% of them required hip replacement (one of them bilaterally). Also 4 patients had been splenectomized. The study with serial MRI demonstrated that once the ERT is initiated none of the bone manifestations (bone infarctions and avascular necrosis) progressed in any of the patients. GD patients present mean values of 25OHD of 27,4±10,5 ng/ml. Insufficient vitamin D levels (25OHD <30 ng/ml) were observed in most GD patients (87%), 14% showed deficient levels (25OHD <20 ng/ml). As for bone remodeling markers we found values of P1NP 60,75±34 ng/ml and bCTX 552±240 pg/ml. None of the patients received supplementation with calcium and vitamin D. According to densitometry criteria 22% of the patients have osteoporosis and 22% are in the range of osteopenia. 1 pathological fracture was registered (vertebral). Conclusions ERT prevents progression of bone abnormalities in GD. Vitamin D insufficiency is frequent in GD and almost half of the patients have decreased bone mass. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.5379

Investigation of nedaplatin and CpG oligodeoxynucleotide combination therapy in a mouse model of lung cancer

“…Its prominent antitumor effects are attributed to its interference with DNA replication, resulting in DNA damage [3]. However, NDP therapy shows some side effects, including bone marrow suppression, renal dysfunction, and immune dysfunction [4].…”